MedTrace Logo

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

NCT03809078 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-01-11

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

Conditions

Interventions

DRUG

68Ga RM2

PET radiopharmaceutical

DRUG

68Ga-PSMA-11

PET radiopharmaceutical

DEVICE

Investigational PET scanner coils and software

GE Healthcare non-approved PET scanner coils and software

Sponsors & Collaborators

  • General Electric

    collaborator INDUSTRY

  • Andrei Iagaru

    lead OTHER

Principal Investigators

  • Andrei H Iagaru, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-14
Primary Completion
2022-03-08
Completion
2022-03-08
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809078 on ClinicalTrials.gov